Jan. 25, 2012
/PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that it has secured two commitments for an aggregate capital raise of CA$3,600,000. This funding is structured as term loans of one year from private lenders secured by the Company's real estate. Interest on the loans is payable monthly at the rate of 10%
"This capital infusion will permit the Company to advance its redevelopment plans, and to do so in a manner that is not dilutive to our stockholders," commented
, Generex's President & Chief Executive Officer.
The first loan, for an aggregate of CA$2,500,000, closed on
, 2012. A portion of the Company's real estate is subject to a prior ranking mortgage in the approximate amount of CA$1,100,000. A portion of the first loan equal to that amount has been placed in escrow pending discharge of the prior ranking mortgage.
The second loan, for an aggregate of CA$1,100,000, is designed to discharge the prior ranking mortgage. The second loan is scheduled to close on or before
January 30, 2012
, whereupon the escrowed portion of the first loan will be released to the Company.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at
or the Antigen Express website at